Table 4.

Activity of Selected Leads in a Series of HCV Lifecycle Assays^a

entry	% RLUb
	HCV-Luc	ATPlite	HCVscc	HCV replicon GT 1bd	HCVppe		MLVppf	VSVppg
					GT 1a	GT 1b
7a	2.16 ± 0.508	90.0 ± 3.0	1.63 ± 1.57	75.2 ± 4.9	21.9 ± 14.7	16.8 ± 6.5	48.7 ± 3.85	61.5 ± 5.2
7ii	0.27 ± 0.07	4.88 ± 0.19	3.92 ± 1.51	9.1 ± 3.0	14.9 ± 11.6	25.3 ± 6.4	57.7 ± 2.4	28.0 ± 3.1
7nn	0.72 ± 0.32	90.4 ± 1.5	3.29 ± 2.06	83.3 ± 7.0	76.8 ± 7.7	16.6 ± 10.5	102 ± 5	77.7 ± 12.0
18a	0.59 ± 0.39	74.1 ± 3.0	4.14 ± 1.94	65.2 ± 3.2	35.1 ± 5.8	31.7 ± 8.5	111 ± 6	78.0 ± 4.9

^aActivity of compound (10 μM) in a series of assays to assess efficacy in different stages of the viral life cycle. Results are presented as percentage response compared to the untreated control.

^bRelative luminescence units.

^cHCV single-cycle infection assay.

^dHCV subgenomic replicon assay.

^eHCV pseudoparticle assay.

^fMurine leukemia virus pseudoparticle assay.

^gVesicular stomatitis virus pseudoparticle assay.